US Stock MarketDetailed Quotes

GRI Bio (GRI)

Watchlist
  • 1.730
  • +0.060+3.59%
Close Aug 17 16:00 ET
  • 1.740
  • +0.010+0.58%
Post 19:55 ET
3.78MMarket Cap-0.61P/E (TTM)

About GRI Bio Company

GRI Bio, Inc. engages in the development and commercialization of therapies for inflammatory, fibrotic, and autoimmune diseases. It focuses on its lead program, GRI-0621, an inhibitor of type 1 invariant Natural Killer T (iNKT) cell activity and is being developed as a novel oral therapeutic for the treatment of idiopathic pulmonary fibrosis. The company was founded in May 2009 and is headquartered in La Jolla, CA.

Company Profile

SymbolGRI
Company NameGRI Bio
Listing DateFeb 10, 2021
ISINUS3622AW5029
Founded2009
CEODr. W. Marc Hertz, PhD
MarketNASDAQ
Employees4
Fiscal Year Ends12-31
Address2223 Avenida De La Playa,Suite 208
CityLa Jolla
ProvinceCalifornia
CountryUnited States of America
Zip Code92037
Phone1-619-400-1170

Company Executives

  • Name
  • Position
  • Salary
  • Dr. W. Marc Hertz, PhD
  • President, Chief Executive Officer and Director
  • 617.22K
  • Leanne M. Kelly
  • Chief Financial Officer and Principal Accounting Officer
  • 469.42K
  • Dr. Vipin Kumar Chaturvedi, PhD
  • Chief Scientific Officer
  • 419.42K
  • Dr. Albert Agro, PhD
  • Chief Medical Officer
  • --
  • David Szekeres
  • Chairman of the Board
  • 91.00K
  • Camilla V. Simpson, M.Sc.
  • Independent Director
  • 64.50K
  • Roelof Rongen
  • Independent Director
  • 57.50K
  • David Baker
  • Independent Director
  • 40.00K
Market Insights
China Concept Stocks
View More
Middle East conflict spreads to the stock market! How should investors respond?
Ahead of the market open, US Treasury Secretary Bessent indicated that the United States and Iran are poised to reach an agreement the follo Show More